Dr Reddy’s Laboratories and OneSource Specialty Pharma have informed the Delhi High Court that they will not sell or market their version of the anti-obesity drug semaglutide in India until the court decides on a patent infringement suit filed by Novo Nordisk.

Key highlights

Patent dispute over semaglutide

• Danish drugmaker Novo Nordisk has accused the Indian firms of infringing its patent for semaglutide, sold globally as Wegovy.

• Dr Reddy’s began manufacturing the drug in April 2025 after receiving a production license in December 2024.

No sales in India but export may continue

• Both companies have assured the court they will not sell the drug in India.

• However, they reserved the right to export the drug to countries where Novo Nordisk does not hold a patent.

Court response and next hearing

• The Delhi HC has officially recorded the undertaking from Dr Reddy’s and OneSource.

• Novo Nordisk argued that exporting a patent-infringing product also violates Indian patent law.

• The next hearing is scheduled for August 19, 2025.

While Dr Reddy’s may continue manufacturing and exporting its version of semaglutide, its sale in India remains on hold pending legal review. The case underscores growing tensions over intellectual property rights in India’s evolving pharmaceutical export landscape.